氯氮平治疗耐药性精神分裂症患者不同血液学监测方案的经济学评价
该研究从医疗系统视角,用半马尔可夫模型模拟10万名耐药性精神分裂症成人,比较英国现行氯氮平血液学监测实践与延长监测间隔、修订中性粒细胞绝对值(ANC)停药标准及两者组合的成本效果与预算影响。结果显示,延长监测可降低人均总成本且不损害生活质量,修订ANC标准可轻微增加QALYs,两者组合为优势策略。
要点
- 延长血液学监测间隔可降低人均总成本且不损害生活质量。
- 修订ANC停药标准可避免不必要的早期停药并轻微增加QALYs。
- 延长监测联合修订ANC标准为优势策略,成本更低且QALYs略增。
核心结论
- 修订英国现行氯氮平监测实践在临床和经济上均有益。
- 调整ANC停药标准避免不必要的早期停药,对生活质量有积极影响。
- 延长监测间隔降低医疗系统成本,且不损害安全性。
研究设计与样本
- 成本效果与预算影响分析,从医疗系统视角,为期3年。
- 使用半马尔可夫模型模拟10万名耐药性精神分裂症成人队列。
- 比较英国现行监测实践与延长监测、修订ANC标准及两者组合,并进行敏感性分析。
主要发现
- 延长监测:人均总成本6388.34 vs 5569.77 GBP,QALYs 795.83 vs 795.79天。
- 修订ANC标准:人均总成本6388.34 vs 6390 GBP,QALYs 795.83 vs 797.08天。
- 联合策略:人均总成本6388.34 vs 5548.50 GBP,QALYs 795.83 vs 797.03天,为优势策略。
关键数值与推荐
- 延长监测人均总成本6388.34 vs 5569.77 GBP,QALYs 795.83 vs 795.79天。
- 修订ANC标准人均总成本6388.34 vs 6390 GBP,QALYs 795.83 vs 797.08天。
- 联合策略人均总成本6388.34 vs 5548.50 GBP,QALYs 795.83 vs 797.03天。
临床怎么用
- 可考虑延长氯氮平治疗患者的血液学监测间隔以降低医疗系统成本。
- 可考虑修订ANC停药标准以避免不必要的早期停药并改善生活质量。
- 联合实施延长监测与修订ANC标准可能为最优策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clozapine is licensed for treatment-resistant schizophrenia (TRS). Because of the risk of clozapine-induced agranulocytosis, its use requires regular haematological monitoring. Substantive evidence supports revisions of absolute neutrophil counts (ANCs) for clozapine discontinuation and ceasing of indefinite haematological monitoring. AIMS: To examine the cost-effectiveness and budget impact of different haematological monitoring schemes compared with the current UK monitoring practice for patients using clozapine. METHOD: We performed a cost-effectiveness and budget impact analysis from the healthcare system perspective over a 3-year period, comparing the current UK clozapine monitoring practice with extended haematological monitoring and a revision of ANC criteria. Costs and quality-adjusted life years (QALYs) were estimated using a semi-Markov model that followed a simulated cohort of 100 000 adults with TRS. Sensitivity analyses were conducted. RESULTS: Extended haematological monitoring would lead to lower mean total costs per patient (6388.34 v. 5569.77 GBP) and not compromise quality of life (in QALYs 795.83 v. 795.79 days). A revision of ANC criteria for clozapine discontinuation would not substantially lower costs (6388.34 v. 6390 GBP), but lead to a slight increase in QALYs (795.83 v. 797.08 days), through patients benefitting from longer clozapine treatment. A combination of extended haematological monitoring and revision of ANC criteria would be the dominant strategy, which means that costs are lower (6388.34 v. 5548.50 GBP) and QALYs slightly increase (795.83 v. 797.03 days) compared with the current UK monitoring practice. CONCLUSIONS: A revision of current UK clozapine monitoring practice would be beneficial from both a clinical and an economic perspective. Adjusting ANC criteria for clozapine cessation avoids unnecessary early discontinuation of clozapine treatment and has a positive impact on quality of life. An extension of monitoring intervals reduces costs borne by the healthcare system. Safety is not compromised by these changes.
引用
- Diederich F, Oloyede E, Taylor D, et al. Economic evaluation of different haematological monitoring schemes for patients with treatment-resistant schizophrenia using clozapine. Br J Psychiatry. 2025. PMID: 41229349. doi:10.1192/bjp.2025.10424
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。